(1) Mechanisms of chronic inflammation and disorders of glucose and lipid mediated organ injuries (atherosclerosis,  lipid disorder of renal diseases, diabetic nephropathy, and non-alcohol fatty liver disease e.t.c);
(2) The role of chronic inflammation and immunity disorder in the progression of glomerular diseases.

(1) 2013, the first prize of Natural Science Award of the Ministry of Education （NO.5);

(2) 2011, Young Scientist Award, November, Beijing, China, the World Hypertension League Regional Congress in conjunction with the 13th International Symposium on Hypertension and Related Diseases;

(3) 2009, the second prize of Science and Technology Progress Award of the Ministry of Education (NO.9);

(4) 2008, the third prize of Chinese Medical Science and Technology Award (NO.6);

(5) 2007, the outstanding sentific presentation in 44th European Dialysis Transplantation Association, Barcelona, Spain;

(6) 2007,Scholarships for outstanding oversea students awarded by National Oversea Scholarship Council.

1). *Ma KL, Zhang Y, Liu J, Wu Y, Hu ZB, Ruan XZ,Liu BC. Establishment of an Inflamed Animal Model of Diabetic Nephropathy. Int J Biol Sci, 10(2): 149-159,2014.(IF=3.168)

2). Ma KL, Ni J, Wang CX, Liu J, Zhang Y,Wu Y, Lv LL, Ruan XZ, Liu BC. Interaction of RAS Activation and Lipid DisordersAccelerates the Progression of Glomerulosclerosis. Int J Med Sci, 10(12):1615-24, 2013. (IF=2.065).

3). Ma KL, Liu J, Wang CX, Ni J, Zhang Y,Wu Y, Lv LL, Ruan XZ, Liu BC. Activation of mTOR modulates SREBP-2 to inducefoam cell formation through increased retinoblastoma protein phosphorylation. Cardiovasc Res,100(3):450-60, 2013. (IF=5.94).

4). Ma KL, Liu J, Wang CX, Ni J, Zhang Y,Wu Y, Lv LL, Ruan XZ, Liu BC. Increased mTORC1 activity contributes toatherosclerosis in apolipoprotein E knockout mice and in vascular smooth musclecells. Int J Cardiol,168(6):5450-3, 2013.(IF=5.509).

5). Ni J, *Ma KL, Wang CX, Liu J, Zhang Y, Lv LL,Ni HF, Chen YX, Ruan XZ, Liu BC. Activation of renin-angiotensin system isinvolved in dyslipidemia-mediated renal injuries in apolipoprotein E knockoutmice and HK-2 cells. LipidsHealth Dis, 12(1):49,2013.(IF=2.015).

6). Ma KL, Liu J, Ni J, Zhang Y, Lv LL,Tang RN, Ni HF, Ruan XZ, Liu BC. Inflammatory stress exacerbates theprogression of cardiac fibrosis in high-fat-fed apolipoprotein E knockout micevia endothelial-mesenchymal transition. Int J Med Sci,10(4):420-6, 2013. (IF=2.065).

7). *Ma KL, Wang CX. Analysis of thespectrum and antibiotic resistance of uropathogens in vitro: results based on aretrospective study from a tertiary hospital. Am J Infect Control, 41(7):601-6, 2013.(IF=2.731).

8). Liu J, *Ma KL, Gao M, Wang CX, Ni J, Zhang Y,Zhang XL, Liu H, Wang YL, Liu BC. Inflammation disrupts the LDL receptorpathway and accelerates the progression of vascular calcification in ESRDpatients. PLoS One, 7(10):e47217, 2012.(IF=3.73).

9). Ma KL, Varghese Z, Ku Y, Powis SH,Chen Y, Moorhead JF, Ruan XZ. Sirolimus inhibits endogenous cholesterolsynthesis induced by inflammatory stress in human vascular smooth muscle cells.Am J Physiol Heart Circ Physiol,298(6):H1646-51, 2010.(IF=3.629).

10). Ma KL, RuanXZ, Powis SH, Chen YX, Moorhead JF, and Varghese Z. Inflammatory stressexacerbates lipid accumulation in hepatic cells and fatty livers ofapolipoprotein E knockout mice. Hepatology,48 (3):770-81, 2008. (IF=12.003).

11). Ma KL, Ruan XZ,Powis SH, Chen Y, Moorhead JF, Varghese Z. Sirolimus modifies cholesterol homeostasis in hepatic cells: apotential molecular mechanism for sirolimus-associated dyslipidemia.Transplantation, 84 (8):1029-36, 2007.(IF=3.781).

12). Ma KL, Ruan XZ,Powis SH, Moorhead JF, and Varghese Z. Anti-atherosclerotic effects ofsirolimus on human vascular smooth muscle cells. Am J Physiol Heart CircPhysiol, 292 (6):H2721-8, 2007. (IF=3.629).